SCIRP Mobile Website
Paper Submission

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

 

Contact Us >>

Article citations

More>>

Mehta, S.R. (2003) Aspirin and clopidogrel in patients with ACS undergoing PCI: CURE and PCI-CURE. Journal of Invasive Cardiology, 15, 17B-20B, Discussion 20B-21B.

has been cited by the following article:

  • TITLE: Clopidogrel in ischemic heart disease: A critical appraisal

    AUTHORS: Mohammed A. Al-Otaiby, Abdulrahman M. Al-Moghairi

    KEYWORDS: Clopidogrel; Ischemic Heart Disease; Thienopyridine; Platelets Inhibition

    JOURNAL NAME: Health, Vol.5 No.3, March 29, 2013

    ABSTRACT: Aspirin and clopidogrel are the commonest dual antiplatelet agents being used in the secondary prevention of cardiovascular disease. In high risk patients with coronary heart disease, the use of aspirin was associated with a significant risk reduction of myocardial infarction, stroke and vascular death. The use of clopidogrel alone was slightly superior to aspirin, and associated with reduced risk of vascular death, ischemic stroke and myocardial infarction. Dual antiplatelet therapy has been well studied in patients with acute coronary syndrome and those undergoing percutaneous coronary intervention (PCI). In patients with stable coronary heart disease or multiple risk factors the combination of clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing MI, stroke or death from cardiovascular causes.